Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well as safe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.

Software Engineering

London, UK

Exogene

Ambitious individuals leave places like Google, Goldman Sachs and Stanford to join EF. Why? Because starting a startup is the highest impact thing you can do with your life.    EF is the best place to find a co-founder, build a company and access the world's best investors. We've helped build over 80 technology companies, collectively worth over $1bn.
EF is backed by Reid Hoffman (founder of LinkedIn) and Greylock Partners, Mosaic Ventures, Founders Fund, Lakestar and some of the world's best entrepreneurs.
Read our manifesto here.

Join aworld-changingstartup

Join a
world-changing
startup